Serial-measured versus estimated creatinine clearance in patients with non-small cell lung cancer receiving cisplatin-based chemotherapy

Journal of the Formosan Medical Association

Volumn 102, Issue 4, 2003, Pages 257-261

  Chang, Gee Chen ^a,b   Yang, Tsung Ying ^a,b   Shih, Chuen Ming ^b   Lin, Long Yau ^b   Lee, Hong Shen ^b   Chiang, Chi Der ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Carcinoma, non small cell lung; Cisplatin; Creatinine

Indexed keywords

ANDROGEN; ASCORBIC ACID; CEFALOTIN; CEFOXITIN; CIMETIDINE; CISPLATIN; COTRIMOXAZOLE; CREATININE; DIURETIC AGENT; LEVODOPA; METHYLDOPA; PENICILLIN G;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SAFETY; FEMALE; HUMAN; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; STATISTICAL SIGNIFICANCE; TAIWAN; UREMIA; UROGENITAL TRACT DISEASE; VOMITING;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CREATININE; FEMALE; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAIWAN;

EID: 0042914542     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hardaker WT, Stone RA, McCoy R: Platinum nephrotoxicity. Cancer 1974;34:1030-2.
2. Ward JM, Young DM, Fauvie KA, et al: Comparative nephrotoxicity of platinum cancer chemotherapeutic agents. Cancer Treat Rep 1976;60:1675-8.
3. Ozols RF, Ihde DC, Linehan WM, et al: A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germcell tumours. J Clin Oncol 1988;6:1031-40.
4. Madias NE, Harrington JT: Platinum nephrotoxicity. Am J Med 1978;65:307-14.
5. Legha SS, Dimery IW: High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. J Clin Oncol 1985;3:1373-8.
6. Humes HD, Weinberg JM: Toxic nephropathies. In: Brenner BM, Rector FC, editors. The Kidney. 3rd ed. Philadelphia: W. B. Saunder; 1986:1491-532.
7. Danovitch GM: Evaluation of renal function. In: Massry SG, Glassock RJ, editors. Textbook of Nephrology. 1st ed. Baltimore: Williams and Wilkins; 1983: 1128-34.
8. Brenner BM, Ichikawa I, Deen WM: Glomerular filtration. In: Brenner BM, Rector FC, editors. The Kidney. 2nd ed. Philadelphia: W. B. Saunders; 1981:289-327.
9. Bennett WM, Porter GA: Endogenous creatinine clearance as a clinical measure of glomerular filtration rate. BMJ 1971;4:84-6.
10. Blachley JD, Hill JB: Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 1981;95:628-32.
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
12. Davila E, Gardner LB: Clinical value of the creatinine clearance before the administration of chemotherapy with cisplatin. Cancer 1987;60:161-4.
13. Patterson WP, Reams GP: Renal toxicities of chemotherapy. Semin Oncol 1992;19:521-8.
14. Kassirer JP: Clinical evaluation of kidney function - glomerular function. N Engl J Med 1971;285:385-9.
15. Janssen I, Heymsfield SB, Baumgartner RN, et al: Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol 2000;89:465-71.
16. Hadj-Aissa A, Dumarest C, Maire P, et al: Renal function in the elderly. Nephron 1990;54:364-5.
17. Larsson M, Jagenburg R, Landahl S: Renal function in an elderly population. A study of S-creatinine, 51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. Scand J Clin Lab Invest 1986;46:593-8.
18. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85.
19. Fliser D, Bischoff I, Hanses A, et al: Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 1999;55:205-11.
20. Judge TG: The miliue interieur and aging. In: Brocklehurst JC, editor. Textbook of Geriatric Medicine and Gerontology. 2nd ed. New York: Churchill Livingstone 1978;291-306.
21. Hrushesky WJ, Shimp W, Kennedy BJ: Lack of age-dependent cisplatin nephrotoxicity. Am J Med 1984;76:579-84.
22. Thyss A, Saudes L, Otto J, et al: Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994;12:2121-5.
23. Ishikawa I, Onouchi Z, Zaito Y: Renal cortex visualization and analysis of dynamic CT curves of the kidney. J Comput Assist Tomogr 1981;5:695-701.
24. Hrushesky WJ, Borch R, Levi F: A circadian time dependence of cisplatin urinary pharmacokinetics. Clin Pharmacol Ther 1982; 32:330-9.
25. Hargis JB, Anderson JR, Propert KJ, et al: Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol 1992;30:291-6.
26. Pasternack A, Kuhlback B: Diurnal variations of serum and urine creatine and creatinine. Scand J Clin Lab Invest 1971;27:1-7.